A combination comprising a compound of Formula (I): ** Formula ** wherein: R1 is hydrogen, C1-3 alkyl, CH2OH, CH2-O-CH3, CH2OCH2Ph, CH2CN, CN, halo or C (O) OCH3 ； R2 is independently hydrogen, CN, CF3, halo, SO2 C1-3alkyl, C1-3alkyl or C≡CH； R3 is hydrogen, C1-2 alkyl, CF3 or OH； R4 is hydrogen, halo or C1-3 alkyl； X is CR4 or N； A is (CH2) n -Het； or A is (CH2) n- (CRaRb) - (CH2) m-Het； Ra is hydrogen or C1-3alkyl, wherein C1-3alkyl may be further substituted with one or more halos； Rb is C1-3 alkyl； or Ra and Rb, together with the carbon atom to which they are attached, forms a C3-6 cycloalkyl group； one or more of the carbon atoms in the C3-6 cycloalkyl group formed by Ra and Rb may be replaced with oxygen to form an oxetane, tetrahydrofuryl or tetrahydropyranyl； one of the carbon atoms in the C3-6 cycloalkyl group formed by Ra and Rb, may be replaced with nitrogen to form a pyrrolidinyl or piperidinyl group； Het is: ** ^ Formula ** where Het can be substituted with one, two or three substituents selected from: halo, C1-5 alkyl, CN, CH2F, CHF2, CF3, C3-6 cycloalkyl, (CH2) nO- C1-3 alkyl, (CH2) n-phenyl, (CH2) n-pyridyl, pyrimidinyl, pyrazinyl, CH (CH3) -O-C1-3 alkyl, CH (OH) -C1-5 alkyl, C (CH3) 2 - R5, C (O) N (CH3) p, N (C1-3 alkyl) p, NH2, C (O) NH2, oxetane, oxetane-CH3, tetrahydrofurfuryl, tetrahydropyranyl, morpholinyl or pyrazolyl； wherein the substituent phenyl, pyrazolyl, and pyridyl in the Het may be further substituted with one or two substituents selected from: halo, CN, OCH3, C1-3 alkyl or CF3； and the substituents C1-5 alkyl and C3-6 cycloalkyl in the Het may be further substituted with CN or OH； R5 is CN, O-C1-4 alkyl, (CH2) m-OH, (CH2) p-O-C (O) -O-C1-5 alkyl or O- (CH2) p-O-R6； R6 is C1-4 alkyl or P (O) 2 (CH3) 2； n is independently 0, 1 or 2； m is independently 0, 1 or 2； p is independently 1 or 2； y y is 1, 2 or 3； or a pharmaceutically acceptable salt thereof； and one or more other therapeutic agents, selected from the group consisting of end
